1. Histone Deacetylase Inhibitors as Anticancer Drugs
   Tomas Eckschlager et al, 2017, IJMS CrossRef
2. Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.
   Azmi Yerlikaya, 0 CrossRef
3. The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells
   Tereza Cerna et al, 2018, IJMS CrossRef
4. Targeting of epigenetic regulators in neuroblastoma
   Luz Jubierre et al, 2018, Exp Mol Med CrossRef
5. α-Diimines as Versatile, Derivatizable Ligands in Ruthenium(II) p-Cymene Anticancer Complexes
   Lorenzo Biancalana et al, 2018, Inorg. Chem. CrossRef
6. Identifying cisplatin-induced kidney damage in paediatric oncology patients
   Chris D. Barton et al, 2018, Pediatr Nephrol CrossRef
7. Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells
   Sangiliyandi Gurunathan et al, 2018, Molecules CrossRef
8. Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
   Xuejiao Li et al, 2018, Bioinorganic Chemistry and Applications CrossRef
9. Vincristine combination with Ca+2 channel blocker increase antitumor effects
   Ali Taghizadehghalehjoughi et al, 2019, Mol Biol Rep CrossRef
10. Anticancer Activity of Spirocyclic Hydroxamic Acids (Derivatives of 1-Hydroxy-1,4,8-Triazaspiro[4,5]Decan-2-One), Histone Deacetylase Inhibitors
    N. P. Akentieva et al, 2019, Biochem. Moscow Suppl. Ser. A CrossRef
11. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors
    Anna Macieja et al, 2019, Mol Biol Rep CrossRef
12. Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma
    Mohamed Ashraf Khalil et al, 2016, PLoS ONE CrossRef
13. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
    Reza Bayat Mokhtari et al, 2017, BMC Cancer CrossRef
14. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer
    Hoyoung Ryu et al, 2019, Biological & Pharmaceutical Bulletin CrossRef
15. Drug repurposing towards targeting cancer stem cells in pediatric brain tumors
    Hisham F. Bahmad et al, 2020, Cancer Metastasis Rev CrossRef
16. Peptide-Carbon Quantum Dots conjugate, Derived from Human Retinoic Acid Receptor Responder Protein 2, against Antibiotic-Resistant Gram Positive and Gram Negative Pathogenic Bacteria
    Aninda Mazumdar et al, 2020, Nanomaterials CrossRef
17. Neuroprotective Potential and Antioxidant Activity of Various Solvent Extracts and Essential Oil of Ferula orientalis L.
    Elif Feyza Topdas et al, 2020, Journal of Essential Oil Bearing Plants CrossRef
18. Comparative gene expression profiling of human metallothionein-3 up-regulation in neuroblastoma cells and its impact on susceptibility to cisplatin
    Miguel Angel Merlos Rodrigo et al, 2018, Oncotarget CrossRef
19. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
    Loredana Cappellacci et al, 2020, CMC CrossRef
20. Characterization and in vitro Analysis of Probiotic-Derived Peptides Against Multi Drug Resistance Bacterial Infections
    Aninda Mazumdar et al, 2020, Front. Microbiol. CrossRef
21. Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
    Hirva Mamdani et al, 2020, Front. Cell Dev. Biol. CrossRef
22. Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
    João Lobo et al, 2020, Cancers CrossRef
23. Preparation of CoS nanoparticles-cisplatin bio-conjugates and investigation of their effects on SH-SY5Y neuroblastoma cell line
    Muhammed Sait Ertugrul et al, 2020, Cytotechnology CrossRef
24. The effects of MgS nanoparticles-Cisplatin-bio-conjugate on SH-SY5Y neuroblastoma cell line
    Ozge Balpinar Nalci et al, 2020, Mol Biol Rep CrossRef
25. Cellular Molecular and Proteomic Profiling Deciphers the SIRT1 Controlled Cell Death Pathways in Esophageal Adenocarcinoma Cells
    Huige Jiang et al, 2020, Cancer Treatment and Research Communications CrossRef
26. Double hit: Synchronous gastrointestinal stromal tumour (GIST) & lung neuroendocrine tumour − a rare case of multiple primary malignancies
    KadliShirish Kumar et al, 2021, J Assoc Chest Physicians CrossRef
27. Metallothionein-3 promotes cisplatin chemoresistance remodelling in neuroblastoma
    Miguel Angel Merlos Rodrigo et al, 2021, Sci Rep CrossRef
28. HDAC2 and 7 down-regulation induces senescence in dermal fibroblasts
    Céline Warnon et al, 2021, Aging CrossRef
29. In Vitro Determination of Valproic Acid and Cisplatin Combination Antitumor Effect on Neuroblastoma Tumors Viability
    Ali TAGHİZADEHGHALEHJOUGHİ et al, 2021 CrossRef
30. Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs
    Roberto Ciaccio et al, 2021, IJMS CrossRef
31. Short-Chain Fatty Acid Butyrate Induces Cilia Formation and Potentiates the Effects of HDAC6 Inhibitors in Cholangiocarcinoma Cells
    Kishor Pant et al, 2022, Front. Cell Dev. Biol. CrossRef
32. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes
    Gheath Alatrash et al, 2022, Transplantation and Cellular Therapy CrossRef
33. The histone deacetylase inhibitor OBP‐801 has in vitro / in vivo anti‐neuroblastoma activity
    Daisuke Kaneda et al, 2022, Pediatrics International CrossRef
34. DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine
    Guodong Zhang et al, 2022, EPMA Journal CrossRef
35. null
    Kenneth S. Ramos et al, 2023 CrossRef
36. Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death
    Diego Iglesias-Corral et al, 2024, Front. Oncol. CrossRef